Table 1 Baseline patient characteristics
SRRSH cohort (N = 3214) | CHLP cohort (N = 16,273) | |||||||
|---|---|---|---|---|---|---|---|---|
Characteristics | Her2 zero | Her2 low | Her2 positive | p | Her2 zero | Her2 low | Her2 positive | p |
All patients | 1009 | 1399 | 806 | 5662 | 6471 | 4140 | ||
Age, years | ||||||||
Median age(range), years | 58(26–94) | 57(25–91) | 57(28–83) | 55(10–96) | 55(23–92) | 55(18–89) | ||
Age | 0.044b | <0.001b | ||||||
<30 | 2(0.20%) | 6(0.43%) | 1(0.12%) | 52(0.92%) | 55(0.85%) | 51(1.23%) | ||
30–39 | 47(4.66%) | 71(5.08%) | 47(5.83%) | 440(7.77%) | 530(8.19%) | 331(8.00%) | ||
40–49 | 180(17.84%) | 263(18.80%) | 121(15.01%) | 1414(24.97%) | 1687(26.07%) | 940(22.71%) | ||
50–59 | 401(39.74%) | 530(37.88%) | 334(41.44%) | 1746(30.84%) | 1979(30.58%) | 1274(30.77%) | ||
60–69 | 267(26.46%) | 379(27.09%) | 225(27.92%) | 1382(24.41%) | 1592(24.60%) | 1058(25.56%) | ||
>70 | 112(11.10%) | 150(10.72%) | 78(9.68%) | 628(11.09%) | 628(9.70%) | 486(11.74%) | ||
Stagea | 0.074c | <0.001c | ||||||
Early | 842(83.45%) | 1136(81.20%) | 663(82.26%) | 2594(45.81%) | 4715(72.86%) | 2945(71.14%) | ||
Advanced | 127(12.59%) | 224(16.01%) | 122(15.14%) | 3024(53.41%) | 1650(25.50%) | 1118(27.00%) | ||
Missing | 40(3.96%) | 39(2.79%) | 21(2.61%) | 44(0.78%) | 106(1.64%) | 77(1.86%) | ||
Tumor status | 0.232b | <0.001b | ||||||
T1 | 523(51.83%) | 771(55.11%) | 405(50.25%) | 2694(47.58%) | 2778(42.93%) | 2223(53.70%) | ||
T2 | 429(42.52%) | 562(40.17%) | 355(44.04%) | 2003(35.38%) | 3282(50.72%) | 1549(37.42%) | ||
T3 | 21(2.08%) | 23(1.64%) | 23(2.85%) | 756(13.35%) | 268(4.14%) | 208(5.02%) | ||
T4 | 1(0.10%) | 4(0.29%) | 2(0.25%) | 159(2.81%) | 37(0.57%) | 83(2.00%) | ||
X | 0(0.00%) | 2(0.14%) | 2(0.25%) | NA | NA | NA | ||
Missing | 35(3.47%) | 37(2.64%) | 19(2.36%) | 50(0.88%) | 106(1.64%) | 77(1.86%) | ||
Nodal status | <0.001b | <0.001b | ||||||
N0 | 568(56.29%) | 686(49.04%) | 475(58.93%) | 2461(43.47%) | 3397(52.50%) | 2581(62.34%) | ||
N1 | 320(31.71%) | 492(35.17%) | 212(26.30%) | 1908(33.70%) | 2675(41.34%) | 1153(27.85%) | ||
N2 | 86(8.52%) | 152(10.86%) | 77(9.55%) | 941(16.62%) | 245(3.79%) | 266(6.43%) | ||
N3 | 33(3.27%) | 68(4.86%) | 41(5.09%) | 341(6.02%) | 147(2.27%) | 129(3.12%) | ||
X | 1(0.10%) | 0(0.00%) | 1(0.12%) | NA | NA | NA | ||
Missing | 1(0.10%) | 1(0.07%) | 0(0.00%) | 11(0.19%) | 7(0.11%) | 11(0.27%) | ||
Intravascular cancer thrombus | 0.164c | <0.001c | ||||||
Yes | 62(6.14%) | 105(7.51%) | 68(8.44%) | 1034(18.26%) | 383(5.92%) | 565(13.65%) | ||
No | 947(93.86%) | 1294(92.49%) | 738(91.56%) | 4628(81.74%) | 6088(94.08%) | 3575(86.35%) | ||
Histologic type | <0.001b | <.001b | ||||||
Invasive ductal carcinoma | 872(86.42%) | 1260(90.06%) | 765(94.91%) | 4705(83.10%) | 5432(83.94%) | 3888(93.91%) | ||
Invasive lobular carcinoma | 29(2.87%) | 43(3.07%) | 9(1.12%) | 580(10.24%) | 632(9.77%) | 115(2.78%) | ||
Others | 107(10.60%) | 92(6.58%) | 31(3.85%) | 377(6.66%) | 407(6.29%) | 137(3.31%) | ||
Missing | 1(0.10%) | 4(0.29%) | 1(0.12%) | NA | NA | NA | ||
ER status | <0.001c | <0.001 | ||||||
Negative | 381(37.76%) | 311(22.23%) | 455(56.45%) | 1497(26.44%) | 1370(21.17%) | 1210(29.23%) | ||
Positive | 627(62.14%) | 1088(77.77%) | 351(43.55%) | 4165(73.56%) | 5101(78.83%) | 2930(70.77%) | ||
Missing | 1(0.10%) | 0(0.00%) | 0(0.00%) | NA | NA | NA | ||
PgR status | <0.001c | <0.001c | ||||||
Negative | 506(50.15%) | 638(45.60%) | 629(78.04%) | 2110(37.27%) | 2086(32.24%) | 1920(46.38%) | ||
Positive | 502(49.75%) | 759(54.25%) | 174(21.59%) | 3552(62.73%) | 4385(67.76%) | 2220(53.62%) | ||
Missing | 1(0.10%) | 2(0.14%) | 3(0.37%) | NA | NA | NA | ||
Subtype | <0.001b | <0.001b | ||||||
Luminal A | 278(27.55%) | 462(33.02%) | 0(0.00%) | 2829(49.96%) | 2246(34.71%) | 0(0.00%) | ||
Luminal B/HER2 negative | 239(23.69%) | 400(28.59%) | 0(0.00%) | 1099(19.41%) | 2877(44.46%) | 0(0.00%) | ||
Luminal B/HER2 positive | 0(0.00%) | 0(0.00%) | 351(43.55%) | 0(0.00%) | 0(0.00%) | 2988(72.17%) | ||
HER2 positive | 0(0.00%) | 0(0.00%) | 441(54.71%) | 0(0.00%) | 0(0.00%) | 1152(27.83%) | ||
Triple negative | 370(36.67%) | 303(21.66%) | 0(0.00%) | 1446(25.54%) | 1277(19.73%) | 0(0.00%) | ||
Missing | 122(12.09%) | 234(16.73%) | 14(1.74%) | 288(5.09%) | 71(1.10%) | 0(0.00%) | ||
Endocrine therapy | <0.001c | <0001c | ||||||
Yes | 647(64.12%) | 1100(78.63%) | 380(47.15%) | 4034(71.25%) | 5107(78.92%) | 2824(68.21%) | ||
No | 245(24.28%) | 232(16.58%) | 293(36.35%) | 1424(25.15%) | 1257(19.43%) | 1092(26.38%) | ||
Missing | 117(11.60%) | 67(4.79%) | 133(16.50%) | 204(3.60%) | 107(1.65%) | 224(5.41%) | ||
Radiation therapy | <0.001c | <0.001c | ||||||
Yes | 606(60.06%) | 916(65.48%) | 429(53.23%) | 3786(66.87%) | 3919(60.56%) | 2368(57.20%) | ||
No | 383(37.96%) | 439(31.38%) | 352(43.67%) | 1847(32.62%) | 2428(37.52%) | 1751(42.29%) | ||
Missing | 20(1.98%) | 44(3.15%) | 25(3.10%) | 29(0.51%) | 124(1.92%) | 21(0.51%) | ||
Her2 target therapy | <0.001c | <0.001c | ||||||
Yes | 4(0.40%) | 14(1.00%) | 431(53.47%) | 0(0.00%) | 0(0.00%) | 1895(45.77%) | ||
No | 1005(99.60%) | 1385(99.00%) | 375(46.53%) | 5662(100.00%) | 6471(100.00%) | 2245(54.23%) | ||
Ki67 index | <0.001b | |||||||
<15% | 295(29.24%) | 533(38.10%) | 118(14.64%) | 2035(35.94%) | 1291(19.95%) | 737(17.80%) | <0.001b | |
15–35% | 280(27.75%) | 500(35.74%) | 356(44.17%) | 2304(40.69%) | 3044(47.04%) | 1891(45.68%) | ||
>35% | 356(35.28%) | 324(23.16%) | 295(36.60%) | 1035(18.28%) | 2065(31.91%) | 1459(35.24%) | ||
Missing | 78(7.73%) | 42(3.00%) | 37(4.59%) | 288(5.09%) | 71(1.10%) | 53(1.28%) | ||
Chemotherapy protocols | <0.001b | NA | ||||||
EC + T | 323(32.01%) | 376(26.88%) | 132(16.38%) | NA | NA | NA | ||
FEC | 113(11.20%) | 50(3.57%) | 61(7.57%) | NA | NA | NA | ||
TC | 222(22.00%) | 376(26.88%) | 52(6.45%) | NA | NA | NA | ||
Chemo+Target | 158(15.66%) | 322(23.02%) | 71(8.81%) | NA | NA | NA | ||
Others | 96(9.51%) | 169(12.08%) | 190(23.57%) | NA | NA | NA | ||
Missing | 97(9.61%) | 106(7.58%) | 300(37.22%) | NA | NA | NA | ||
Vital status | <0.001c | <0.001c | ||||||
Alive | 920(91.18%) | 1349(96.43%) | 764(94.79%) | 4975(87.87%) | 5956(92.04%) | 3866(93.38%) | ||
Deceased | 67(6.64%) | 39(2.79%) | 36(4.47%) | 669(11.82%) | 480(7.42%) | 253(6.11%) | ||
Missing | 22(2.18%) | 11(0.79%) | 6(0.74%) | 18(0.32%) | 35(0.54%) | 21(0.51%) | ||
Recurrence | 0.019c | NA | ||||||
Yes | 88(8.72%) | 81(5.79%) | 53(6.58%) | NA | NA | NA | ||
No | 921(91.28%) | 1318(94.21%) | 753(93.42%) | NA | NA | NA | ||
